首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide.
【24h】

Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide.

机译:使用MS2噬菌体衣壳和HIV-1 TAT细胞穿透肽的结合物开发反义RNA递送系统。

获取原文
获取原文并翻译 | 示例
           

摘要

RNA-based therapeutic strategies are used widely due to their highly specific mode of action. However, the major obstacle in any RNA-based therapy is cellular delivery and stability in the cells. The self-assembly of the MS2 bacteriophage capsids has been used to develop virus-like particles (VLPs) for drug delivery. In this study, we utilized the heterobifunctional crosslinker, sulfosuccinimidyl-4-(p-maleimidophenyl)-butyrate (sulfo-SMPB), to conjugate the human immunodeficiency virus-1 (HIV-1) Tat peptide and MS2 VLPs; the antisense RNA against the 5'-untranslated region (UTR) and the internal ribosome entry site (IRES) of the hepatitis C virus (HCV) was packaged into these particles by using a two-plasmid coexpression system. The MS2 VLPs conjugated with the Tat peptide were then transferred into Huh-7 cells containing an HCV reporter system. The packaged antisense RNA showed an inhibitory effect on the translation of HCV. This paper describes our initial results with this system using the Tat peptide.
机译:基于RNA的治疗策略因其高度特异性的作用方式而被广泛使用。但是,任何基于RNA的治疗方法的主要障碍是细胞传递和细胞稳定性。 MS2噬菌体衣壳的自组装已被用于开发病毒样颗粒(VLP)用于药物递送。在这项研究中,我们利用异双功能交联剂磺基丁二酰亚胺-4-(对-马来酰亚胺基苯基)丁酸酯(磺基SMPB)来缀合人类免疫缺陷病毒1(HIV-1)Tat肽和MS2 VLP。通过使用两质粒共表达系统,将针对丙型肝炎病毒(HCV)的5'非翻译区(UTR)和内部核糖体进入位点(IRES)的反义RNA包装到这些颗粒中。然后将与Tat肽缀合的MS2 VLP转移到含有HCV报告系统的H​​uh-7细胞中。包装的反义RNA显示出对HCV翻译的抑制作用。本文介绍了使用Tat肽的该系统的初步结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号